“FCGBP inhibits the development of LSCC and cisplatin resistance through the PIGR/JAK2/STAT3 pathway”, Radiol Oncol, vol. 60, no. 1, pp. 67–75, Mar. 2026, Accessed: Jul. 28, 2026. Available: https://www.ojstest.computing.si/index.php/ro/article/view/4672